Skip to Content

Xyralid LP (hydrocortisone / lidocaine topical) Disease Interactions

There are 10 disease interactions with Xyralid LP (hydrocortisone / lidocaine topical):

Major

Lidocaine (Includes Xyralid LP) ↔ Teething Pain

Severe Potential Hazard, Moderate plausibility

Applies to: Teething Syndrome

Topical lidocaine is not recommended to be used in teething infants and young children, as its ingestion is dangerous and potentially fatal. Ingestion of the drug has shown to result in seizures, severe brain injury, and heart problems in children.

Major

Lidocaine Topical (Includes Xyralid LP) ↔ Cardiovascular Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Heart Block, Shock

Lidocaine is absorbed through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic effects. At high plasma levels, lidocaine can cause hypotension, bradycardia, and cardiovascular collapse. Therapy with lidocaine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded. Children and debilitated, elderly, or acutely ill patients should be given reduced dosages commensurate with their age, weight, and physical condition.

Major

Lidocaine Topical (Includes Xyralid LP) ↔ Hepatic Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Lidocaine is rapidly and extensively metabolized by the liver. Less than 10% is eliminated unchanged in the urine. Several inactive and two active forms (MEGX and GX) have been identified. MEGX and GX exhibit antiarrhythmic and convulsant properties. The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow. Therapy with lidocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic function.

Major

Lidocaine Topical (Includes Xyralid LP) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Lidocaine is primarily eliminated by the kidney. Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties. Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment. Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated doses in patients with compromised renal function.

Major

Lidocaine Topical (Includes Xyralid LP) ↔ Seizures

Severe Potential Hazard, Moderate plausibility

Applies to: Seizures

Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Seizures can occur as a result of accumulation of active metabolites. Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.

Moderate

Topical Corticosteroids (Includes Xyralid LP) ↔ Diabetes

Moderate Potential Hazard, Low plausibility

Applies to: Abnormal Glucose Tolerance, Diabetes Mellitus

Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia. Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration. Use of occlusive dressings over the applied areas may also increase percutaneous absorption. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.

References

  1. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  2. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  3. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  4. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  5. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  6. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  7. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  8. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  9. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  10. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  11. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  12. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  13. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  14. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  15. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  16. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  17. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  18. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  19. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  20. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  21. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  22. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  23. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
View all 23 references
Moderate

Topical Corticosteroids (Includes Xyralid LP) ↔ Diaper Rash

Moderate Potential Hazard, High plausibility

Applies to: Diaper Rash

Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing's syndrome and intracranial hypertension because of their larger skin surface to body mass ratios. If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.

References

  1. Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979): 362-3
  2. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  3. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  4. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  5. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22
  6. Nathan AW, Rose GL "Fatal iatrogenic Cushing's syndrome." Lancet 1 (1979): 207
  7. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  8. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  9. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  10. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  11. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  12. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  13. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  14. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  15. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
  16. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  17. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  18. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  19. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983): 1130-1
  20. Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987): 422-4
  21. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  22. Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983): 475-80
  23. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  24. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976): 612-3
  25. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  26. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  27. Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977): 1196-202
  28. Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983): 59-71
  29. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  30. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  31. Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993): 501-3
  32. Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995): 950-5
  33. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  34. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  35. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  36. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing's syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982): 274-5
  37. Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991): 61-2
View all 37 references
Moderate

Topical Corticosteroids (Includes Xyralid LP) ↔ Hyperadrenocorticism

Moderate Potential Hazard, Low plausibility

Applies to: Hyperadrenocorticism

The use of topical corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.

References

  1. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976): 612-3
  2. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  3. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  4. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  5. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  6. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  7. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing's syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982): 274-5
  8. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  9. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  10. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22
  11. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  12. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  13. Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983): 475-80
  14. Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990): 107-11
  15. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  16. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  17. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  18. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  19. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  20. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  21. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  22. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  23. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  24. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
  25. Nathan AW, Rose GL "Fatal iatrogenic Cushing's syndrome." Lancet 1 (1979): 207
  26. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  27. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983): 1130-1
  28. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  29. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  30. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  31. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  32. Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991): 61-2
View all 32 references
Moderate

Topical Corticosteroids (Includes Xyralid LP) ↔ Infections

Moderate Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral, Tuberculosis -- Latent

Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used. Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. Occlusive dressings should not be used in patients with skin infection.

References

  1. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  2. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  3. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
  4. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  5. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  6. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  7. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  8. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  9. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  10. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  11. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  12. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  13. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  14. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  15. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  16. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  17. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  18. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  19. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  20. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  21. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  22. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  23. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  24. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
View all 24 references
Moderate

Topical Corticosteroids (Includes Xyralid LP) ↔ Ocular Toxicities

Moderate Potential Hazard, Low plausibility

Applies to: Cataracts, Glaucoma/Intraocular Hypertension

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.

References

  1. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  2. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  4. Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976): 207-8
  5. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  6. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  7. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  8. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  9. Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983): 878-81
  10. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  11. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  12. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  13. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  14. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  15. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  16. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  17. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  18. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  19. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  20. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  21. Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976): 492-5
  22. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  23. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  24. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  25. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  26. Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993): 664-6
  27. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
View all 27 references

Xyralid LP (hydrocortisone / lidocaine topical) drug Interactions

There are 76 drug interactions with Xyralid LP (hydrocortisone / lidocaine topical)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide